Welcome to our dedicated page for Halliburton SEC filings (Ticker: HAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halliburton’s financial story is written across hundreds of pages that detail frac fleet utilization, drilling technology spend, and litigation reserves. Yet finding the specific note on North American margins or the exact Form 4 entry showing when executives bought shares before an oil rally can be time-consuming. Stock Titan solves that problem by turning Halliburton’s complex disclosures into concise, searchable insights.
AI-powered summaries break down every 10-K and 10-Q so you can understand how commodity prices move segment revenue without reading line-by-line. Need the latest Halliburton quarterly earnings report 10-Q filing or want Halliburton SEC filings explained simply? You’ll see real-time highlights the moment a document hits EDGAR. Our platform also tracks Halliburton insider trading Form 4 transactions, giving you Form 4 insider transactions in real time and flagging patterns that may precede material 8-K events.
- Halliburton annual report 10-K simplified � quickly locate capex on pressure-pumping assets
- Halliburton proxy statement executive compensation � see how pay aligns with drilling cycles
- Halliburton 8-K material events explained � from contract wins to environmental settlements
- Halliburton earnings report filing analysis � compare quarter-over-quarter segment margins
- Understanding Halliburton SEC documents with AI � skip jargon, focus on what drives cash flow
Whether you monitor Halliburton executive stock transactions Form 4 for insider sentiment or need a granular view of hydraulic fracturing demand, Stock Titan provides comprehensive coverage with real-time updates. Make informed decisions faster—no manual page flipping required.
Halliburton (HAL) Q2 2025 10-Q highlights
- Top-line: Revenue fell 6% YoY to $5.51 bn; North America �9%, Latin America �11%. Europe/Africa/CIS +8% was the lone growth region.
- Profitability: Operating income declined 30% to $727 m; margin compressed to 13.2% (17.7%). Net income attributable to shareholders dropped 33% to $472 m; EPS $0.55 vs $0.80.
- YTD impact: $356 m of severance, asset and facility impairments drove a 47% EPS contraction to $0.78 and lifted the effective tax rate to 25.5%.
- Cash & leverage: Operating cash flow down 19% to $1.27 bn; FCF after $656 m capex was $0.62 bn. Cash balance slipped to $2.04 bn (-22%) while total debt held steady at $7.16 bn; no near-term covenant pressure and $3.5 bn credit revolver available.
- Capital returns: 12 m shares repurchased for $252 m; 21.5 m YTD for $507 m. Quarterly dividend maintained at $0.17; board still targeting �50% of annual FCF to shareholders.
- Segment trends: Completion & Production revenue �7%, operating income �29%; Drilling & Evaluation revenue �4%, operating income �23%—reflecting weaker pressure pumping, Saudi/Mexico activity cuts and price pressure.
- Outlook: Management now expects 2025 revenue to decline in both North America and internationally, citing tariff-related demand uncertainty and faster-than-expected OPEC+ supply. Capex guidance unchanged at ~6% of revenue.
- Risks: $909 m CDS exposure to Mexican customer, potential $640 m tax cash outflow from IRS dispute, and SAP S4 migration costs may extend beyond prior $270 m estimate.
Corcept Therapeutics Incorporated (Nasdaq: CORT) filed a Form 8-K dated 14 July 2025 to disclose a material corporate event under Item 8.01 (Other Events).
The company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for its selective cortisol modulator relacorilant to treat patients with platinum-resistant ovarian cancer. An attached press release (Exhibit 99.1) provides additional detail and is incorporated by reference. No financial results, guidance or transactional information accompanied the filing.
This NDA submission represents a significant regulatory milestone that, if approved, could diversify Corcept’s revenue base by moving the company beyond its current endocrinology focus into the oncology market. Timing of FDA review (typically 10-12 months) and eventual commercialization remain contingent on agency acceptance and approval.
Northpointe Bancshares, Inc. (NYSE: NPB) filed an 8-K on June 26, 2025 disclosing new three-year employment agreements for four key executives. The contracts cover Amy M. Butler (EVP National Sales), David J. Christel (President, Mortgage Purchase Program), Kevin J. Comps (President, Company & Bank) and Brad T. Howes (EVP & CFO). Each agreement automatically renews for successive one-year terms unless 90-days� written notice of non-renewal is given.
Compensation framework
- Base salaries: Butler $200k; Christel $175k; Comps $400k; Howes $300k (all subject to annual review).
- Performance incentives: Butler—quarterly incentive equal to the greater of $75k or 2 % of residential-lending quarterly net income (if profitable); Christel—monthly incentive of 4 % of MPP net income plus annual bonus of 1 % of MPP net income above $1 m; Comps—annual bonus target 100 % of salary; Howes—annual bonus target 50 % of salary.
Severance protection
- Termination without cause or for good reason: multiple applied to (salary + target/average bonus). Multiples are 1.5× for Christel & Comps and 1.0× for Butler & Howes.
- Change-in-control terminations (within 12 months): multiples rise to 2.0× for Christel & Comps and 1.5× for Butler & Howes.
- Company pays COBRA premiums for 18 months; executives must sign release and observe one-year non-compete/non-solicitation.
The agreements supersede prior contracts for Christel (2017) and Comps (2020). Payments subject to potential parachute-payment excise-tax cut-back to maximize executives� after-tax benefit.
No immediate financial metrics were provided, but the contracts formalize retention of senior leadership and outline potentially higher variable compensation costs tied to unit profitability. Full agreements will be filed with the Q2 2025 Form 10-Q.